Dyadic International, Inc. filings document the regulatory disclosures of a Nasdaq-listed biotechnology company developing and commercializing recombinant proteins and enzymes through proprietary microbial expression platforms. Form 8-K reports cover financial results, press-release exhibits, business-development updates, and Nasdaq continued-listing matters affecting the company's common stock.
The filing record also includes material agreements and capital-structure disclosures, including equity issuance programs under shelf registration statements, underwriting arrangements for common stock offerings, and amendments to security agreements tied to senior secured convertible promissory notes. These documents describe Dyadic's governance, registered securities, financing activity, listing compliance, and formal event reporting.
Bandera Partners LLC, together with Managing Members Gregory Bylinsky and Jefferson Gramm, filed an amended Schedule 13G reporting ownership of 1,383,308 shares of Dyadic International, Inc. common stock as of June 30, 2025. Those shares represent 4.6% of the outstanding class based on 30,090,661 shares reported by the issuer on May 13, 2025. The shares are directly held by Bandera Master Fund L.P.; Bandera Partners is the investment manager with authority to vote and dispose of the shares, and Messrs. Bylinsky and Gramm are reported as managing members with shared voting and dispositive power. The filing states the position is held in the ordinary course of business and not for control purposes.
Dyadic International, Inc. filed a Form 8-K to let investors know it has released its financial results for the quarter ended June 30, 2025. The company distributed these results through a press release dated August 13, 2025.
The press release is included as Exhibit 99.1 and is described as being furnished rather than filed under the securities laws, which affects how it is treated for liability and incorporation into other SEC filings.
Dyadic International, Inc. reported results for the quarter ended June 30, 2025, showing revenue growth and a smaller operating loss versus the prior year. Total revenue was $966,630 for the quarter (versus $385,896 a year earlier) and $1,360,202 for the six months (versus $720,513). Net loss for the quarter was $(1,793,774) compared with $(2,045,223) a year ago; six-month net loss was $(3,821,353) versus $(4,054,819). Basic and diluted loss per share was $(0.06) for the quarter and $(0.13) for six months.
Balance sheet and liquidity highlights show cash and cash equivalents of $2,140,899 and restricted cash of $1,833,531 related to the Gates Foundation grant. Total assets were $8.14 million and total liabilities $8.67 million, producing stockholders' equity of $(529,701). Convertible notes net carrying amounts were $1,070,971 (related party) and $3,930,170 (third party). Post-period the company closed an offering on August 1, 2025 that generated net proceeds of approximately $5.3 million; management states existing funds plus the offering are expected to cover at least 12 months, subject to assumptions stated in the filing.
Dyadic International, Inc. (Nasdaq: DYAI) received a Nasdaq Listing Qualifications notice on 17-Jul-2025 after its common stock failed to meet the $1.00 minimum bid price for the past 30 consecutive business days, violating Rule 5550(a)(2).
The notice does not immediately affect DYAI’s listing. The company has 180 calendar days—until 13-Jan-2026—to regain compliance by achieving a closing bid of at least $1.00 for 10 consecutive trading days. If the requirement is unmet, Dyadic may qualify for a second 180-day grace period, provided it satisfies all initial listing standards other than bid price and formally notifies Nasdaq of its remediation plan. Failure to cure could result in delisting, with the option to appeal.
Management “intends to actively monitor” share price and explore alternatives to resolve the deficiency. The filing also reminds investors that the company remains out of compliance with the $35 million Market Value of Listed Securities rule (Rule 5550(b)(2)); that separate deficiency must be remedied by 20-Dec-2025. Either unresolved deficiency can independently trigger delisting.